Activity of quinolones against Chlamydia pneumoniae

Drugs

Volumn 58, Issue SUPPL. 2, 1999, Pages 78-81

  Hammerschlag, Margaret R ^a,b  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b Box 49 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CLARITHROMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; SULFAMETHOXAZOLE; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; NONHUMAN; RESPIRATORY TRACT INFECTION;

4-QUINOLONES; ANIMALS; ANTI-INFECTIVE AGENTS; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FLUOROQUINOLONES; HUMANS;

BACTERIA (MICROORGANISMS); CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE;

EID: 0032708273     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958002-00015     Document Type: Conference Paper

References (37)

1. Grayston JT, Kuo CC, Wang SP, et al. A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med 1986; 315: 161-8
2. Grayston JT, Campbell LA, Kuo C-C, et al. A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR. J Infect Dis 1990; 161: 618-25
3. Mundy PM, Oldach D, Amcaerler PG, et al. Implications for macrolide treatment in community-acquired pneumonia. Chest 1998; 113: 1201-6
4. Fang GD, Fine M, Orloff et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. Medicine 1990; 69: 307
5. Gaydos CA, Eiden JJ, Oldach D, et al. Diagnosis of Chlamydia pneumoniae infections in patients with community-acquired pneumonia by polymerase chain reaction enzyme immunoassay. Clin Infect Dis 1994; 19: 157-60
6. Norrby SR. Atypical pneumonia in the Nordic countries: aetiology and clinical results of a trial comparing fleroxacin and doxycycline. Nordic Atypical Pneumonia Study Group. J Antimicrob Chemother 1997; 39: 499-508
7. Porath A, Schlaeffer F, Lieberman D. The epidemiology of community-acquired pneumonia among hospitalized adults. J Infect 1997; 34: 41-8
8. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization. Arch Intern Med 1997; 157: 1709-18
9. Block S, Hedrick J, Hammerschlag MR, et al. Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate. Pediatr Infect Dis J 1995; 14: 471-7
10. Harris JAS, Kolokathis A, Campbell M, et al. Safety and efficacy of azithromycin in the treatment of community acquired pneumonia in children. Pediatr Infect Dis J 1998; 17: 865-71
11. Grayston JT, Aldous MB, Easton A, et al. Evidence that Chlamydia pneumoniae causes pneumonia and bronchitis. J Infect Dis 1993; 168: 1231-5
12. Emre U, Roblin PM, Gelling M, et al. The association of Chlamydia pneumoniae infection and reactive airway disease in children. Arch Pediatr Adolesc Med 1994; 148: 727-32
13. Block SL, Hammerschlag MR, Hedrick J, et al. Chlamydia pneumoniae in acute otitis media. Pediatr Infect Dis J 1997; 16: 855-62
14. Hammerschlag MR, Chirgwin K, Roblin PM, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178-82
15. Dean D, Roblin PM, Mandel L, et al. Molecular evaluation of serial isolates from patients with persistent Chlamydia pneumoniae infections. In: Stephens RS, Byrne GI, Christiansen G, et al. editors Chlamydial infections: Proceedings of the Ninth International Symposium on Human Chlamydial Infection. San Francisco: USCF; 1998: 219-23
16. Weiss SM, Hammerschlag MR. Are heart attacks infectious? A critical look at the link between Chlamydia pneumoniae and atherosclerosis. Bull Inst Pasteur 1997; 95: 107-13
17. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1873-8
18. Hammerschlag MR, Hyman CL, Roblin PM. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 682-3
19. Roblin PM, Montalban G, Hammerschlag MR. In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1402-3
20. Roblin PM, Kutlin A, Hammerschlag MR. In vitro activity of trovafloxacin against Chlamydia pneumoniae. Antimicrob Agents Chemother 1997; 41: 2033-4
21. Roblin PM, Hammerschlag MR. In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998; 42: 951-2
22. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin L-ofloxacin and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-4
23. Miyashita N, Niki Y, Kishimoto T, et al. In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp. Antimicrob Agents Chemother 1997; 41: 1331-4
24. Kimura M, Kishimoto T, Niki Y, et al. In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents. Antimicrob Agents Chemother 1993; 37: 801-3
25. Dessus-Babus S, Bebear CM, Charron A, et al. Sequencing of gyrase and topoisomerase IV quinolone-resistance-determining regions of Chlamydia trachomatis and characterization of quinolone-resistant mutants obtained in vitro. Antimicrob Agents Chemother 1998; 42: 2474-81
26. Ridgway GL, Salman H, Clark S, et al. Comparative in vitro activity against Legionella pneumophila and Chlamydia spp. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25-27; San Diego. Washington DC: American Society for Microbiology
27. Roblin PM, Hammerschlag MR. In vitro activity of a new quinolone, S-34109, against Chlamydia pneumoniae and C. trachomatis. Proceedings of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 25-27; San Diego. Washington DC: American Society for Microbiology
28. Roblin PM, Hammerschlag MR. In vitro activity of a new quinolone, Y-688, against Chlamydia pneumoniae and C. trachomatis. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1997 Sep 28-Oct 1; Toronto. Washington DC: American Society for Microbiology
29. Lipsky BA, Tack KJ, Kuo CC, et al. Ofloxacin treatment of Chlamydia pneumoniae (Strain TWAR) lower respiratory tract infections. Am J Med 1990; 89: 722-4
30. Plouffe JE, Herbert MT, File TM, et al. Ofloxacin versus standard therapy in treatment of community-acquired pneumonia requiring hospitalization. Antimicrob Agents Chemother 1996; 40: 1175-9
31. File TM, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41: 1965-72
32. Leophonte P, Baldwin RJT, Pluck N. Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis. Eur J Clin Microbiol Infect Dis 1998; 17: 434-40
33. Deabate CA, Henry D, Bensch G, et al. Sparfloxacin vs ofloxacin in the treatment of acute bacterial exacerbations of chronic bronchitis - a multicenter, double-blind, randomized, comparative study. Chest 1998; 114: 120-30
34. Hyman CL, Roblin PM, Gaydos CA, et al. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: assessment by polymerase chain reaction-enzyme immunoassay and culture. Clin Infect Dis 1995; 20: 1174-8
35. Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994; 38: 1588-9
36. Roblin PM, Hammerschlag MR. Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother 1998; 42: 194-6
37. Bartlett JG, Breiman RF, Mandell LA, et al. Community-acquired pneumonia in adults: guidelines for management. Clin Infect Dis 1998; 26: 811-38